Evidence map›Paper›PMID 35262089›Full record

ArticlemedRxiv : the preprint server for health sciences2022

Duration of viable virus shedding in SARS-CoV-2 omicron variant infection.

Julie Boucau, Caitlin Marino, James Regan, Rockib Uddin, Manish C Choudhary, James P Flynn, Geoffrey Chen, Ashley M Stuckwisch, Josh Mathews, May Y Liew and 16 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 34 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors at 5 institutions in 1 country.

Julie BoucauRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
Caitlin MarinoRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
James ReganBrigham and Women's Hospital Boston, MA, USA.
Rockib UddinMassachusetts General Hospital, Boston, MA, USA.
Manish C ChoudharyBrigham and Women's Hospital Boston, MA, USA.
James P FlynnBrigham and Women's Hospital Boston, MA, USA.
Geoffrey ChenMassachusetts General Hospital, Boston, MA, USA.
Ashley M StuckwischMassachusetts General Hospital, Boston, MA, USA.
Josh MathewsMassachusetts General Hospital, Boston, MA, USA.
May Y LiewMassachusetts General Hospital, Boston, MA, USA.
Arshdeep SinghMassachusetts General Hospital, Boston, MA, USA.
Taryn LipinerMassachusetts General Hospital, Boston, MA, USA.
Autumn KittilsonBrigham and Women's Hospital Boston, MA, USA.
Meghan MelbergBrigham and Women's Hospital Boston, MA, USA.
Yijia LiBrigham and Women's Hospital Boston, MA, USA.
Rebecca F GilbertMassachusetts General Hospital, Boston, MA, USA.
Zahra ReynoldsMassachusetts General Hospital, Boston, MA, USA.
Surabhi L IyerMassachusetts General Hospital, Boston, MA, USA.
Grace C ChamberlinMassachusetts General Hospital, Boston, MA, USA.
Tammy D VyasMassachusetts General Hospital, Boston, MA, USA.
Marcia B GoldbergMassachusetts General Hospital, Boston, MA, USA.
Jatin M VyasMassachusetts General Hospital, Boston, MA, USA.
Jonathan Z LiBrigham and Women's Hospital Boston, MA, USA.
Jacob E LemieuxMassachusetts General Hospital, Boston, MA, USA.
Mark J SiednerMassachusetts General Hospital, Boston, MA, USA.
Amy K BarczakRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
Massachusetts General Hospital · USBrigham and Women's Hospital · USHarvard University · USRagon Institute of MGH, MIT and Harvard · USBroad Institute · US

Funding

The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI RAJESH T GANDHI · 2004 to 2026
$94.4M
NIAID NIH HHS P30 AI060354
6 · The paper itself

Abstract

Clinical features of SARS-CoV-2 Omicron variant infection, including incubation period and transmission rates, distinguish this variant from preceding variants. However, whether the duration of shedding of viable virus differs between omicron and previous variants is not well understood. To characterize how variant and vaccination status impact shedding of viable virus, we serially sampled symptomatic outpatients newly diagnosed with COVID-19. Anterior nasal swabs were tested for viral load, sequencing, and viral culture. Time to PCR conversion was similar between individuals infected with the Delta and the Omicron variant. Time to culture conversion was also similar, with a median time to culture conversion of 6 days (interquartile range 4-8 days) in both groups. There were also no differences in time to PCR or culture conversion by vaccination status.

Identifiers

PMID35262089
PMCPMC8902872
OpenAlexW4214943884

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.